- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region � Global Forecast to 2031
USD 14.53 BN
MARKET SIZE, 2031
CAGR 10.9%
(2026-2031)
300
REPORT PAGES
250
MARKET TABLES
PREFILLED SYRINGES MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global prefilled syringes market, valued at USD 7.82 billion in 2025, stood at USD 8.65 billion in 2026 and is projected to advance at a resilient CAGR of 10.9% from 2026 to 2031, culminating in a forecasted valuation of USD 14.53 billion by the end of the period. Prefilled syringes are a convenient way to deliver parenteral medications or a single-dose packet of medication with a premeasured dose. This drug administration method offers manufacturers advantages in terms of reducing drug waste and extending product lifespan. Additionally, it provides ease of self-administration for patients at home and in non-hospital settings. Some examples of drugs packaged in prefilled syringes include biologics, vaccines, blood stimulants, therapeutic proteins, erythropoietin products, and interferons.
KEY TAKEAWAYS
-
BY TYPE
By type, the conventional syringes segment dominated the prefilled syringes market in 2025, accounting for a share of 84.1%.
-
BY DESIGN
By design, the single-chamber prefilled syringes segment held the largest share of the market at 61.0% in 2025.
-
BY MATERIAL
By material, the glass syringes segment led the prefilled syringes market in 2025, capturing a share of 64.8%.
-
BY APPLICATION
By application, the cancer segment is expected to register the highest CAGR of 13.7% during the forecast period.
-
BY REGION
By region, the Asia pacific is expected to grow at the highest CAGR of 12.5% during the forecast period.
-
COMPETITIVE LANDSCAPE - KEY PLAYERS
BD, Gerresheimer AG, and SCHOTT were identified as some of the star players in the prefilled syringes market, given their strong market shares and product/service footprints.
-
COMPETITIVE LANDSCAPE - STARTUPS
Companies such as 3CK and Sure MedTech have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The prefilled syringes market is propelled by the increasing prevalence of chronic diseases, the rise in demand for self-administration, and the advantages of prefilled syringes such as reduced risk of contamination and dosing errors. Additionally, technological advancements in drug delivery systems and growing adoption of biologics are further accelerating market expansion. Supportive regulatory frameworks and increased focus on patient convenience and safety also contribute significantly to sustained growth.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The transition in the prefilled syringes market is from a largely traditional revenue base toward a future dominated by advanced, polymer, silicone-free, and connected syringe technologies. It highlights how pharmaceutical companies, contract research and manufacturing organizations, and healthcare end users are driving demand for scalable, high-quality, and patient-centric injectable delivery solutions. These shifts aim to improve drug stability, patient safety, operational efficiency, and long-term treatment outcomes across the healthcare ecosystem.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Increasing prevalence of chronic diseases
-
Growing adoption of self-injection devices
RESTRAINTS
Impact
Level
-
Stringent government regulations
OPPORTUNITIES
Impact
Level
-
Growing preference for unit-dose medication using prefilled syringes
-
Emerging markets with growing healthcare infrastructure
CHALLENGES
Impact
Level
-
Alternative drug delivery methods
-
Infections associated with needlestick injuries
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The rising prevalence of chronic diseases is a key factor contributing to the growth of the prefilled syringes market. Conditions like diabetes, cardiovascular diseases, arthritis, and autoimmune disorders require consistent and often lifelong medication management. Prefilled syringes provide a convenient, safe, and efficient way to administer these medications, easing the burden on patients and healthcare systems. They ensure accurate dosing, reduce the risk of contamination and needlestick injuries, and enhance patient compliance by simplifying the self-administration process. Conditions like diabetes, cancer, neurological disorders, inflammatory bowel diseases, lung disorders, severe pancreatitis, and renal failure are major causes of death worldwide. As the world's population ages and chronic diseases become more common, there will be an increasing need for prefilled syringes. These syringes are essential for patients who need regular and precise treatment. This growing demand is also driven by progress in biopharmaceuticals and the manufacturing of biologic drugs, which often require prefilled syringes due to their sensitivity to contamination and the need for accurate doses. Thus, with the increasing prevalence of several chronic diseases worldwide, the demand for advanced and effective drug delivery technologies is expected to rise, which will drive the market growth of prefilled syringes.
Government regulations play a critical role in limiting the growth of the prefilled syringes market by imposing strict requirements and lengthy approval processes for manufacturers. These regulations are in place to ensure the safety, efficacy, and quality of medical products, including both the drug and the delivery device. Prefilled syringes, classified as combination products, must meet strict criteria established by regulatory authorities. Prefilled syringes require thorough examination from both pharmaceutical and medical device perspectives. Extensive clinical trials are necessary to demonstrate the safety and effectiveness of the combination, including stability studies, biocompatibility tests, and human trials. These trials are time-consuming and expensive, often requiring years of research and significant financial investment. The regulatory approval process demands detailed documentation on manufacturing processes, quality control measures, and post-market surveillance plans. Manufacturers must implement and maintain rigorous quality control systems, adhering to Good Manufacturing Practices (GMP), to ensure consistent product quality and safety. Meeting these requirements can delay product launches, as companies need to thoroughly prepare and submit comprehensive data packages for review. While necessary for patient safety, the strict regulatory environment creates major obstacles to entering and expanding the market for prefilled syringes. The high costs and lengthy timelines required to meet these regulations can discourage investment and innovation, thereby restraining the growth of the market.
The expanding healthcare infrastructure in emerging markets presents a promising opportunity for the prefilled syringes market. These regions, which include many developing countries, are experiencing rapid growth in healthcare facilities, access to medical services, and overall healthcare spending. Prefilled syringes offer several advantages that align well with the needs of these emerging markets. Firstly, they provide enhanced safety and reliability in medication delivery. By prefilling precise doses of medications, prefilled syringes reduce the risk of dosing errors and contamination, which is crucial in settings where healthcare resources may be limited or where strict infection control measures are necessary. Secondly, the use of prefilled syringes can enhance healthcare efficiency by simplifying the medication administration process. They require minimal preparation time compared to traditional vials or ampoules. This allows healthcare providers to dedicate more time to patient care, ultimately reducing overall treatment times. This efficiency is particularly beneficial in environments with high patient volumes and limited healthcare staff. Additionally, prefilled syringes offer versatility and adaptability to meet diverse healthcare needs. They can be designed to accommodate various drug formulations and dosages, catering to the specific treatment requirements of local populations. This flexibility supports the delivery of a wide range of medications, including vaccines, biologics, and therapeutic agents, thereby addressing a broad spectrum of healthcare challenges prevalent in emerging markets.
Alternative drug delivery methods pose a significant challenge to the prefilled syringes market, impacting adoption rates and market growth. Several alternative delivery systems, each with unique advantages and applications, directly compete with prefilled syringes in various healthcare settings. Autoinjectors combine the convenience of prefilled syringes with automated injection mechanisms, making them popular for self-administration of medications. They are widely used for emergency treatments (e.g., epinephrine for allergic reactions) and chronic conditions (e.g., autoimmune diseases). Autoinjectors offer precise dosing, ease of use, and portability, which appeals to patients who prefer a user-friendly, ready-to-administer option. Pen injectors have become a strong competitor to prefilled syringes, especially for self-administration of medications. They offer similar convenience to prefilled syringes with a pre-measured dose and a user-friendly injection mechanism. This makes them ideal for patients requiring frequent injections for chronic conditions like diabetes. However, pen injectors may not be compatible with all medications or offer the same level of flexibility as prefilled syringes. For example, some pen injectors are designed for single use with a prefilled cartridge, limiting the ability to adjust the dosage.
PREFILLED SYRINGES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Advanced glass and polymer prefilled syringes with safety features and integrated drug-delivery compatibility for biologics and chronic therapies. | Reduced medication errors, improved drug stability, enhanced patient safety, consistent dose accuracy, and improved usability for self-administration. |
|
|
High-quality glass and plastic prefilled syringes and cartridges for vaccines, biologics, and high-value injectables, supported by fill-finish and CDMO capabilities. | Improved drug container integrity, scalability from clinical to commercial volumes, reduced contamination risk, and reliable supply continuity. |
|
|
Premium pharmaceutical glass tubing and prefillable syringe systems optimized for sensitive biologics and vaccines, with advanced quality control and defect-reduction technologies. | Enhanced drug stability and shelf life, minimized particulate risk, superior dimensional accuracy, reduced breakage, and improved regulatory confidence. |
|
|
Integrated prefilled syringe components, elastomeric closures, and containment systems designed to protect injectable drugs throughout fill-finish and administration. | Preservation of drug potency, reduced extractables risk, improved container-closure integrity, higher fill-finish efficiency, and lower batch failure rates. |
|
|
Advanced drug delivery systems and injectable components supporting prefilled syringe formats, including user-centric and combination-product solutions. | Improved patient adherence, enhanced ease of use, differentiated drug delivery performance, reduced administration errors, and stronger product lifecycle value. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The prefilled syringes market represents a highly interconnected healthcare ecosystem encompassing manufacturers, distributors, regulators, and end users, each playing a critical role in ensuring safe, efficient, and scalable drug delivery. Manufacturers such as BD, SCHOTT, Gerresheimer, and West Pharmaceutical Services drive innovation through the development of advanced glass and polymer prefilled syringes, elastomeric components, and integrated drug–device solutions. Their focus on drug stability, compatibility with biologics, silicone-free systems, and patient-centric designs supports the growing demand for vaccines, biologics, and self-administered injectable therapies while enhancing safety and reducing medication errors. Distributors, including McKesson, Cardinal Health, and Henry Schein, enable broad market access by leveraging extensive logistics networks and digital ordering platforms. They act as vital intermediaries connecting manufacturers with pharmaceutical companies, hospitals, clinics, and pharmacies, ensuring reliable supply, cold-chain integrity, and timely availability across care settings. End users, such as pharmaceutical and biotechnology companies (e.g., Novartis, Sanofi) and leading healthcare providers (e.g., Cleveland Clinic and Mayo Clinic), rely on prefilled syringes to improve dosing accuracy, streamline clinical workflows, and support large-scale immunization and chronic disease management programs. Finally, regulatory bodies including the US FDA, European Medicines Agency (EMA), China’s NMPA, and Japan’s PMDA oversee product approval, quality standards, and safety compliance. Their regulations ensure patient protection, product reliability, and global harmonization—while reimbursement frameworks and healthcare policies directly influence adoption rates and commercial viability of advanced prefilled syringe technologies.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
By type, the prefilled syringes market is segmented conventional prefilled syringes and safety prefilled syringes. In 2025, conventional prefilled syringes accounted for the largest share of the prefilled syringes market due to several factors, including their widespread adoption, cost-effectiveness, and proven reliability. These syringes, which come preloaded with medication, offer significant advantages such as reduced medication errors, improved dosing accuracy, and enhanced patient safety. Their convenience for both healthcare professionals and patients, combined with the growing prevalence of chronic diseases requiring regular injections, further drives their dominance in the market. Additionally, advancements in syringe materials and manufacturing technologies have improved the safety and usability of conventional prefilled syringes, solidifying their market leadership.
By material, the prefilled syringes market is segmented into glass prefilled syringes and plastic prefilled syringes. Glass prefilled syringes dominate the prefilled syringes market due to their superior chemical compatibility, which minimizes interactions with a wide range of pharmaceutical drugs, ensuring drug stability and efficacy. Their excellent barrier properties prevent oxygen and moisture from entering, preserving the medication's integrity over time. Additionally, the robust and inert nature of glass makes it highly resistant to breakage and contamination, offering enhanced safety and reliability. The well-established manufacturing processes for glass syringes also contribute to their widespread adoption, providing consistency and quality assurance in drug delivery systems.
By design, the prefilled syringes market is segmented into single-chamber, dual-chamber, and customized prefilled syringes. In 2025, the single-chamber prefilled syringes segment has emerged as the dominant force in the prefilled syringes market due to their numerous advantages, including ease of use, enhanced patient safety, and reduction in medication errors. These syringes are preloaded with a precise dose of medication, minimizing the need for manual preparation and decreasing the risk of contamination. Their convenience and reliability make them highly preferred in various medical settings, particularly for administering vaccines, biologics, and emergency medications. Furthermore, the growing trend towards self-administration of drugs and the increasing demand for advanced drug delivery systems contribute to the rising adoption of single-chamber prefilled syringes, solidifying their leading position in the market.
By application, the prefilled syringes market is segmented into diabetes, rheumatoid arthritis, anaphylaxis, cancer, thrombosis, ophthalmology, and other applications. In 2025, the cancer segment is projected to hold the largest market share of the prefilled syringes market due to the rising prevalence of cancer globally, which necessitates frequent and precise administration of injectable medications. Prefilled syringes offer numerous advantages, including reducing the risk of dosage errors, minimizing contamination, and enhancing patient safety, which are critical in oncology treatments. The increasing adoption of biologics and biosimilars for cancer therapy, which often require parenteral administration, further drives the demand for prefilled syringes. Additionally, the convenience and efficiency they provide for both healthcare professionals and patients make prefilled syringes a preferred choice in cancer treatment regimens, contributing to their dominant market position.
PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX
In the prefilled syringes market matrix, BD (Star) leads with scale, extensive distribution, and a broad solutions portfolio. AptarGroup, Inc. (Emerging Leader) is gaining momentum with innovative products and packaging technologies. While BD dominates through reach, AptarGroup's innovation positions it for rapid growth toward the leaders’ quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- BD (US)
- Gerresheimer AG (Germany)
- SCHOTT AG (Germany)
- Stevanato Group
- West Pharmaceutical Services, Inc. (US)
- AptarGroup, Inc. (US)
- Nipro (Japan)
- Baxter (US)
- Owen Mumford Ltd. (UK)
- Weigao Medical International Co., Ltd. (China)
- Credence MedSystems, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 7.82 Billion |
| Market Forecast in 2031 (Value) | USD 14.53 Billion |
| CAGR | 10.9% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion), Volume (Thousand Units) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa, GCC Countries |
| Related Segment & Geographic Reports |
Europe Prefilled Syringes Market Asia Pacific Prefilled Syringes Market North America Prefilled Syringes Market |
WHAT IS IN IT FOR YOU: PREFILLED SYRINGES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis |
|
Identify interconnections and potential supply chain blind spots within the injectable drug delivery ecosystem. |
| Company Information | Key players: BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US). | Insights on revenue shifts towards emerging innovations. |
RECENT DEVELOPMENTS
- April 2025 : Gerresheimer partnered with Injecto to launch new silicone oil- and PFAS-free syringe systems, expanding its portfolio with next-generation solutions designed to meet rising regulatory and drug-formulation requirements.
- October 2024 : BD collaborated with Ypsomed to enhance self-injection solutions for high-viscosity biologic drugs. The collaboration integrated BD’s Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector, enabling efficient drug delivery for viscosities over 15cP. These initiatives improved patient experience and accelerated pharmaceutical product development.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
25
2
EXECUTIVE SUMMARY
30
3
PREMIUM INSIGHTS
35
4
MARKET OVERVIEW
40
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
INCREASING PREVALENCE OF CHRONIC DISEASES
4.2.1.2
GROWING ADOPTION OF SELF-INJECTION DEVICES
4.2.1.3
INCREASING ADOPTION OF PREFILLED SYRINGES IN PARENTERAL DOSAGE FORMS
4.2.1.4
INCREASED USE OF BIOLOGICS AND VACCINES
4.2.1.5
TECHNOLOGICAL ADVANCEMENTS IN PREFILLED SYRINGES
4.2.2
RESTRAINTS
4.2.2.1
STRINGENT GOVERNMENT REGULATIONS
4.2.2.2
IMPACT OF PRODUCT RECALLS
4.2.3
OPPORTUNITIES
4.2.3.1
GROWING PREFERENCE FOR UNIT-DOSE MEDICATION USING PREFILLED SYRINGES
4.2.3.2
EMERGING MARKETS WITH GROWING HEALTHCARE INFRASTRUCTURE
4.2.4
CHALLENGES
4.2.4.1
ALTERNATIVE DRUG DELIVERY METHODS
4.2.4.2
INFECTIONS ASSOCIATED WITH NEEDLESTICK INJURIES
4.3
UNMET NEEDS & WHITE SPACES
4.3.1
UNMET NEEDS
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER- 1/2/3 PLAYERS
5
INDUSTRY TRENDS
50
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
GDP TRENDS AND FORECAST
5.2.2
TRENDS IN PREFILLED SYRINGES MARKET
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
SUPPLY CHAIN ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE, 2022–2025
5.6.2
AVERAGE SELLING PRICE TREND OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025
5.6.3
AVERAGE SELLING PRICE TREND OF SAFETY PREFILLED SYRINGES, BY REGION, 2022–2025
5.6.4
AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025
5.7
TRADE ANALYSIS
5.7.1
IMPORT DATA FOR HS CODE 901831
5.7.2
EXPORT DATA FOR HS CODE 901831
5.8
KEY CONFERENCES & EVENTS, 2026
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.10
INVESTMENT & FUNDING SCENARIO
5.11
CASE STUDY ANALYSIS
5.11.1
ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS
5.11.2
DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
5.12
IMPACT OF 2025 US TARIFF ON PREFILLED SYRINGES MARKET
5.12.1
INTRODUCTION
5.12.2
KEY TARIFF RATES
5.12.3
PRICE IMPACT ANALYSIS
5.12.3.1
IMPACT ON COUNTRY/REGION
5.12.3.1.1
US
5.12.3.1.2
EUROPE
5.12.3.1.3
ASIA PACIFIC
5.12.4
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
69
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
KEY TECHNOLOGIES
6.1.1.1
INTEGRATION DISINFECTION UNIT (IDU)
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
CYCLIC OLEFIN POLYMERS (COP) AND CYCLIC OLEFIN COPOLYMERS (COC)
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
INTEGRATION WITH AUTOINJECTORS
6.2
TECHNOLOGY/PRODUCT ROADMAP
6.2.1
SHORT-TERM |RECENT TECHNOLOGIES| FOUNDATION & EARLY COMMERCIALIZATION
6.2.2
MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION
6.2.3
LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION
6.3
PATENT ANALYSIS
6.3.1
PATENT PUBLICATION TRENDS FOR PREFILLED SYRINGES
6.3.2
INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.3.3
LIST OF PATENTS
6.4
IMPACT OF AI/GEN AI ON PREFILLED SYRINGES MARKET
6.4.1
TOP USE CASES AND MARKET POTENTIAL
6.4.2
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.3
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREFILLED SYRINGES MARKET
6.5
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
6.5.1
STEVANATO GROUP: AI-DRIVEN VISUAL INSPECTION FOR PREFILLED SYRINGES
6.5.2
SCHOTT PHARMA: AI-ENABLED SMART GLASS & DEFECT PREDICTION
6.5.3
GERRESHEIMER: PREDICTIVE QUALITY CONTROL IN FILL-FINISH OPERATIONS
7
REGULATORY LANDSCAPE
80
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.2
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
84
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
BUYING CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
PREFILLED SYRINGES MARKET, BY TYPE
87
9.1
INTRODUCTION
9.2
CONVENTIONAL PREFILLED SYRINGES
9.2.1
DISPOSABLE PREFILLED SYRINGES
9.2.1.1
INCREASING FOCUS ON PATIENT SAFETY TO DRIVE MARKET
9.2.2
REUSABLE PREFILLED SYRINGES
9.2.2.1
COST-EFFECTIVENESS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
9.3
SAFETY PREFILLED SYRINGES
9.3.1
INTEGRATED SAFETY FEATURES TO BOOST ADOPTION
10
PREFILLED SYRINGES MARKET, BY DESIGN
97
10.1
INTRODUCTION
10.2
SINGLE-CHAMBER PREFILLED SYRINGES
10.2.1
CONVENIENCE, SAFETY, AND EFFICIENCY OF SINGLE-CHAMBER SYRINGES TO SUPPORT MARKET GROWTH
10.3
DUAL-CHAMBER PREFILLED SYRINGES
10.3.1
ABILITY TO MAINTAIN STABILITY, MINIMIZE DOSING ERRORS, AND MEET REGULATORY STANDARDS TO PROPEL MARKET GROWTH
10.4
CUSTOMIZED PREFILLED SYRINGES
10.4.1
EASY-TO-READ DOSAGE INDICATORS AND SAFETY MECHANISMS TO BOOST ADOPTION
11
PREFILLED SYRINGES MARKET, BY MATERIAL
104
11.1
INTRODUCTION
11.2
GLASS PREFILLED SYRINGES
11.2.1
ABILITY OF GLASS PREFILLED SYRINGES TO OFFER SUPERIOR BARRIER PROPERTIES TO BOOST MARKET GROWTH
11.3
PLASTIC PREFILLED SYRINGES
11.3.1
IMPROVED SAFETY, COST-EFFECTIVENESS, VERSATILITY, AND CONVENIENCE TO SUPPORT ADOPTION
12
PREFILLED SYRINGES MARKET, BY APPLICATION
109
12.1
INTRODUCTION
12.2
DIABETES
12.2.1
INCREASING PREVALENCE OF DIABETES TO FAVOR MARKET GROWTH
12.3
RHEUMATOID ARTHRITIS
12.3.1
RISING DEMAND FOR EFFECTIVE AND CONVENIENT TREATMENT OPTIONS TO AID MARKET GROWTH
12.4
ANAPHYLAXIS
12.4.1
CONVENIENCE OF PREFILLED SYRINGES TO ADMINISTER MEDICATION QUICKLY TO BOOST ADOPTION
12.5
CANCER
12.5.1
RISING GLOBAL CANCER RATES TO SPUR MARKET GROWTH
12.6
THROMBOSIS
12.6.1
MINIMIZED RISK OF CONTAMINATION AND INFECTION ASSOCIATED WITH PREFILLED SYRINGES TO AUGMENT MARKET DEMAND
12.7
OPHTHALMOLOGY
12.7.1
FEWER SIDE EFFECTS ASSOCIATED WITH PREFILLED SYRINGES COMPARED TO TOPICAL MEDICATIONS TO SUPPORT GROWTH
12.8
OTHER APPLICATIONS
13
PREFILLED SYRINGES MARKET, BY REGION
122
13.1
INTRODUCTION
13.2
NORTH AMERICA
13.2.1
US
13.2.1.1
US TO DOMINATE NORTH AMERICAN PREFILLED SYRINGES MARKET DURING FORECAST PERIOD
13.2.2
CANADA
13.2.2.1
INCREASING GOVERNMENT SUPPORT AND RISING INCIDENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH
13.3
EUROPE
13.3.1
GERMANY
13.3.1.1
HIGH INVESTMENT IN HEALTHCARE R&D TO FOSTER INNOVATION IN DRUG DELIVERY TECHNOLOGIES
13.3.2
UK
13.3.2.1
RISING NUMBER OF PATIENTS WITH CARDIOVASCULAR DISEASES AND DIABETES PATIENTS TO FUEL MARKET GROWTH
13.3.3
FRANCE
13.3.3.1
INCREASING INCIDENCE OF NEEDLESTICK INJURIES AND GROWING TREND OF SELF-ADMINISTRATION TO DRIVE MARKET GROWTH
13.3.4
SPAIN
13.3.4.1
INCREASE IN BIOLOGICS PRODUCTION TO SUPPORT MARKET GROWTH
13.3.5
ITALY
13.3.5.1
GROWING FOCUS OF PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES ON HIGH-QUALITY MANUFACTURING STANDARDS TO DRIVE MARKET
13.3.6
REST OF EUROPE
13.4
ASIA PACIFIC
13.4.1
JAPAN
13.4.1.1
INCREASED GERIATRIC POPULATION AND FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT MARKET GROWTH
13.4.2
CHINA
13.4.2.1
LARGE DIABETIC POPULATION TO ATTRACT PHARMACEUTICAL AND DRUG DELIVERY DEVICE MANUFACTURERS TO CHINESE MARKET
13.4.3
INDIA
13.4.3.1
HIGH INCIDENCE OF CANCER AND INCREASED ADOPTION OF BIOSIMILARS TO FUEL MARKET GROWTH
13.4.4
AUSTRALIA
13.4.4.1
GROWING HEALTHCARE EXPENDITURE AND RISING FOCUS ON CHRONIC DISEASE MANAGEMENT TO AID MARKET GROWTH
13.4.5
SOUTH KOREA
13.4.5.1
WELL-DEVELOPED HEALTHCARE SECTOR AND PRESENCE OF MAJOR PHARMACEUTICAL MANUFACTURERS TO DRIVE MARKET
13.4.6
REST OF ASIA PACIFIC
13.5
LATIN AMERICA
13.5.1
BRAZIL
13.5.1.1
INCREASING PREVALENCE OF OBESITY AND RISING USE OF GENERIC MEDICINES TO AID MARKET GROWTH
13.5.2
MEXICO
13.5.2.1
INCREASING FOCUS OF GOVERNMENT ON HEALTHCARE AND GROWING MEDICAL TOURISM TO PROPEL MARKET GROWTH
13.5.3
ARGENTINA
13.5.3.1
INCREASING GERIATRIC POPULATION WITH CHRONIC DISEASES TO FUEL DEMAND FOR PREFILLED SYRINGES
13.5.4
REST OF LATIN AMERICA
13.6
MIDDLE EAST & AFRICA
13.6.1
GROWING PUBLIC HEALTHCARE SPENDING TO BOOST MARKET
13.7
GCC COUNTRIES
13.7.1
INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
14
COMPETITIVE LANDSCAPE
187
14.1
INTRODUCTION
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN PREFILLED SYRINGES MARKET
14.3
REVENUE ANALYSIS, 2020–2024
14.4
MARKET SHARE ANALYSIS, 2025
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.5.1
STARS
14.5.2
EMERGING LEADERS
14.5.3
PERVASIVE PLAYERS
14.5.4
PARTICIPANTS
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
REGION FOOTPRINT
14.5.5.3
TYPE FOOTPRINT
14.5.5.4
MATERIAL FOOTPRINT
14.5.5.5
DESIGN FOOTPRINT
14.5.5.6
APPLICATION FOOTPRINT
14.6
COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
14.6.1
PROGRESSIVE COMPANIES
14.6.2
RESPONSIVE COMPANIES
14.6.3
DYNAMIC COMPANIES
14.6.4
STARTING BLOCKS
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
14.7
BRAND/PRODUCT COMPARISON
14.8
COMPANY VALUATION & FINANCIAL METRICS
14.8.1
FINANCIAL METRICS
14.8.2
COMPANY VALUATION
14.9
R&D EXPENDITURE
14.10
COMPETITIVE SCENARIO
14.10.1
PRODUCT LAUNCHES AND APPROVALS
14.10.2
DEALS
14.10.3
EXPANSIONS
15
COMPANY PROFILES
210
15.1
KEY PLAYERS
15.1.1
BECTON, DICKINSON AND COMPANY (BD)
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS OFFERED
15.1.1.3
RECENT DEVELOPMENTS
15.1.1.3.1
PRODUCT LAUNCHES
15.1.1.3.2
DEALS
15.1.1.3.3
EXPANSIONS
15.1.1.4
MNM VIEW
15.1.1.4.1
RIGHT TO WIN
15.1.1.4.2
STRATEGIC CHOICES
15.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
15.1.2
GERRESHEIMER AG
15.1.3
SCHOTT
15.1.4
WEST PHARMACEUTICAL SERVICES, INC.
15.1.5
APTARGROUP, INC.
15.1.6
NIPRO
15.1.7
BAXTER (SIMTRA BIOPHARMA SOLUTIONS)
15.1.8
OWEN MUMFORD LTD.
15.1.9
WEIGAO MEDICAL INTERNATIONAL CO., LTD.
15.1.10
CREDENCE MEDSYSTEMS, INC.
15.1.11
NOVARTIS AG
15.1.12
STEVANATO GROUP
15.1.13
POLYMEDICURE
15.1.14
AMSINO INTERNATIONAL, INC.
15.1.15
SHARPS TECHNOLOGY, INC.
15.2
OTHER PLAYERS
15.2.1
FRESENIUS KABI USA
15.2.2
MEDEFIL, INC.
15.2.3
D.B.M. S.R.L.
15.2.4
TAISEI KAKO CO., LTD.
15.2.5
SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.
15.2.6
SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.
15.2.7
J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.)
15.2.8
BMI KOREA
15.2.9
B. BRAUN SE
15.2.10
AL SHIFA MEDICAL PRODUCTS CO.
16
RESEARCH METHODOLOGY
272
16.1
RESEARCH DATA
16.1.1
SECONDARY DATA
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
16.1.2
PRIMARY DATA
16.1.2.1
KEY PRIMARY SOURCES
16.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
16.1.2.3
KEY DATA FROM PRIMARY SOURCES
16.1.2.4
KEY INDUSTRY INSIGHTS
16.2
MARKET SIZE ESTIMATION
16.2.1
SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
16.2.2
COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
16.2.3
TOP-DOWN APPROACH
16.3
DATA TRIANGULATION
16.4
MARKET SHARE ESTIMATION
16.5
STUDY ASSUMPTIONS
16.6
RESEARCH LIMITATIONS
16.6.1
METHODOLOGY-RELATED LIMITATIONS
16.7
RISK ASSESSMENT
17
APPENDIX
286
17.1
DISCUSSION GUIDE
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
PREFILLED SYRINGES MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
STANDARD CURRENCY CONVERSION RATES
TABLE 3
UNMET NEEDS IN PREFILLED SYRINGES MARKET
TABLE 4
IMPACT OF PORTER’S FIVE FORCES ON PREFILLED SYRINGES MARKET
TABLE 5
GDP PERCENTAGE CHANGE, BY KEY COUNTRIES, 2021-2030
TABLE 6
ROLE OF COMPANIES IN PREFILLED SYRINGES MARKET ECOSYSTEM ANALYSIS
TABLE 7
AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE, 2022–2025 (USD)
TABLE 8
AVERAGE SELLING PRICE OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025 (USD)
TABLE 9
AVERAGE SELLING PRICE OF SAFETY PREFILLED SYRINGES, BY REGION, 2022–2025 (USD)
TABLE 10
AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025 (USD)
TABLE 11
IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 12
EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 13
PREFILLED SYRINGES MARKET: KEY CONFERENCES & EVENTS, JANUARY 2026–DECEMBER 2026
TABLE 14
CASE STUDY 1: ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS
TABLE 15
CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
TABLE 16
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 17
KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR PREFILLED SYRINGES
TABLE 18
LIST OF MAJOR PATENTS IN PREFILLED SYRINGES MARKET (2022−2025)
TABLE 19
TOP USE CASES AND MARKET POTENTIAL
TABLE 20
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
TABLE 21
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
GLOBAL STANDARDS IN PREFILLED SYRINGES MARKET
TABLE 27
CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN PREFILLED SYRINGES MARKET
TABLE 28
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREFILLED SYRINGES
TABLE 29
KEY BUYING CRITERIA FOR PREFILLED SYRINGES
TABLE 30
UNMET NEEDS FROM END-USE INDUSTRIES IN PREFILLED SYRINGES MARKET
TABLE 31
PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 32
CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 33
CONVENTIONAL PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (MILLION UNITS)
TABLE 34
CONVENTIONAL PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
DISPOSABLE PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
REUSABLE PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
SAFETY PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (MILLION UNITS)
TABLE 38
SAFETY PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 40
SINGLE-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41
DUAL-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
CUSTOMIZED PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 44
GLASS PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
PLASTIC PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46
PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 47
PREFILLED SYRINGES MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
PREFILLED SYRINGES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
PREFILLED SYRINGES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
PREFILLED SYRINGES MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
PREFILLED SYRINGES MARKET FOR THROMBOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
PREFILLED SYRINGES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53
PREFILLED SYRINGES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
NORTH AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
NORTH AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 57
NORTH AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 58
NORTH AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 59
NORTH AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 60
NORTH AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 61
US: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 62
US: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 63
US: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 64
US: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 65
US: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 66
CANADA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 67
CANADA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 68
CANADA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 69
CANADA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 70
CANADA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 71
EUROPE: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
EUROPE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 73
EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 74
EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 75
EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 76
EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 77
GERMANY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 78
GERMANY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79
GERMANY: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 80
GERMANY: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 81
GERMANY: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 82
UK: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83
UK: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 84
UK: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 85
UK: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 86
UK: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 87
FRANCE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 88
FRANCE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 89
FRANCE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 90
FRANCE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 91
FRANCE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 92
SPAIN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 93
SPAIN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 94
SPAIN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 95
SPAIN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 96
SPAIN: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 97
ITALY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98
ITALY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99
ITALY: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 100
ITALY: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 101
ITALY: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 102
REST OF EUROPE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 103
REST OF EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 104
REST OF EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 105
REST OF EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 106
REST OF EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 107
ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 109
ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 110
ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 111
ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 112
ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 113
JAPAN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 114
JAPAN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 115
JAPAN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 116
JAPAN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 117
JAPAN: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 118
CHINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 119
CHINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 120
CHINA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 121
CHINA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 122
CHINA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 123
INDIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 124
INDIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 125
INDIA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 126
INDIA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 127
INDIA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 128
AUSTRALIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129
AUSTRALIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130
AUSTRALIA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 131
AUSTRALIA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 132
AUSTRALIA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 133
SOUTH KOREA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 134
SOUTH KOREA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135
SOUTH KOREA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 136
SOUTH KOREA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 137
SOUTH KOREA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 138
REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139
REST OF ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140
REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 141
REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 142
REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 143
LATIN AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144
LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145
LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146
LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 147
LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 148
LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 149
BRAZIL: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150
BRAZIL: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151
BRAZIL: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 152
BRAZIL: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 153
BRAZIL: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 154
MEXICO: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 155
MEXICO: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 156
MEXICO: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 157
MEXICO: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 158
MEXICO: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 159
ARGENTINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160
ARGENTINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161
ARGENTINA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 162
ARGENTINA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 163
ARGENTINA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 164
REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165
REST OF LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166
REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 167
REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 168
REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 169
MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170
MIDDLE EAST & AFRICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171
MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 172
MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 173
MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 174
GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 175
GCC COUNTRIES: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176
GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION)
TABLE 177
GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION)
TABLE 178
GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 179
OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES IN PREFILLED SYRINGES MARKET
TABLE 180
PREFILLED SYRINGES MARKET: DEGREE OF COMPETITION
TABLE 181
PREFILLED SYRINGES MARKET: REGION FOOTPRINT
TABLE 182
PREFILLED SYRINGES MARKET: TYPE FOOTPRINT
TABLE 183
PREFILLED SYRINGES MARKET: MATERIAL FOOTPRINT
TABLE 184
PREFILLED SYRINGES MARKET: DESIGN FOOTPRINT
TABLE 185
PREFILLED SYRINGES MARKET: APPLICATION FOOTPRINT
TABLE 186
PREFILLED SYRINGES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 187
PREFILLED SYRINGES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY TYPE AND REGION
TABLE 188
PREFILLED SYRINGES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–NOVEMBER 2025
TABLE 189
PREFILLED SYRINGES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 190
PREFILLED SYRINGES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 191
BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
TABLE 192
BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
TABLE 193
BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 194
BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 195
BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 196
GERRESHEIMER AG: COMPANY OVERVIEW
TABLE 197
GERRESHEIMER AG: PRODUCTS OFFERED
TABLE 198
GERRESHEIMER AG: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 199
GERRESHEIMER AG: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 200
GERRESHEIMER AG: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 201
SCHOTT: COMPANY OVERVIEW
TABLE 202
SCHOTT: PRODUCTS OFFERED
TABLE 203
SCHOTT: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 204
SCHOTT: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 205
WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
TABLE 206
WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
TABLE 207
WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 208
WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 209
WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 210
APTARGROUP, INC.: COMPANY OVERVIEW
TABLE 211
APTARGROUP, INC.: PRODUCTS OFFERED
TABLE 212
APTARGROUP, INC.: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 213
APTARGROUP, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 214
NIPRO: COMPANY OVERVIEW
TABLE 215
NIPRO: PRODUCTS OFFERED
TABLE 216
NIPRO: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 217
NIPRO: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 218
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY OVERVIEW
TABLE 219
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCTS OFFERED
TABLE 220
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 221
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 222
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 223
OWEN MUMFORD LTD.: COMPANY OVERVIEW
TABLE 224
OWEN MUMFORD LTD.: PRODUCTS OFFERED
TABLE 225
OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 226
OWEN MUMFORD LTD.: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 227
WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY OVERVIEW
TABLE 228
WEIGAO MEDICAL INTERNATIONAL CO., LTD.: PRODUCTS OFFERED
TABLE 229
CREDENCE MEDSYSTEMS, INC.: COMPANY OVERVIEW
TABLE 230
CREDENCE MEDSYSTEMS, INC.: PRODUCTS OFFERED
TABLE 231
NOVARTIS AG: COMPANY OVERVIEW
TABLE 232
NOVARTIS AG: PRODUCTS OFFERED
TABLE 233
NOVARTIS AG: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 234
STEVANATO GROUP: COMPANY OVERVIEW
TABLE 235
STEVANATO GROUP: PRODUCTS OFFERED
TABLE 236
STEVANATO GROUP: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026
TABLE 237
STEVANATO GROUP: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 238
STEVANATO GROUP: EXPANSIONS, JANUARY 2022–FEBRUARY 2026
TABLE 239
POLYMEDICURE: COMPANY OVERVIEW
TABLE 240
POLYMEDICURE: PRODUCTS OFFERED
TABLE 241
AMSINO INTERNATIONAL, INC.: COMPANY OVERVIEW
TABLE 242
AMSINO INTERNATIONAL, INC.: PRODUCTS OFFERED
TABLE 243
AMSINO INTERNATIONAL, INC.: DEALS, JANUARY 2022–FEBRUARY 2026
TABLE 244
SHARPS TECHNOLOGY, INC.: COMPANY OVERVIEW
TABLE 245
SHARPS TECHNOLOGY, INC.: PRODUCTS OFFERED
TABLE 246
FRESENIUS KABI USA: COMPANY OVERVIEW
TABLE 247
MEDEFIL, INC.: COMPANY OVERVIEW
TABLE 248
D.B.M. S.R.L.: COMPANY OVERVIEW
TABLE 249
TAISEI KAKO CO., LTD.: COMPANY OVERVIEW
TABLE 250
SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.: COMPANY OVERVIEW
TABLE 251
SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.: COMPANY OVERVIEW
TABLE 252
J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.): COMPANY OVERVIEW
TABLE 253
BMI KOREA: COMPANY OVERVIEW
TABLE 254
B. BRAUN SE: COMPANY OVERVIEW
TABLE 255
AL SHIFA MEDICAL PRODUCTS CO.: COMPANY OVERVIEW
TABLE 256
PREFILLED SYRINGES MARKET: STUDY ASUSMPTIONS
TABLE 257
PREFILLED SYRINGES MARKET: RISK ASSESSMENT
LIST OF FIGURES
FIGURE 1
PREFILLED SYRINGES MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
PREFILLED SYRINGES MARKET: YEARS CONSIDERED
FIGURE 3
KEY INSIGHTS AND MARKET HIGHLIGHTS
FIGURE 4
PREFILELD SYRINGES MARKET SIZE, 2026–2031 (USD MILLION)
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PREFILLED SYRINGES MARKET
FIGURE 6
DISRUPTIVE TRENDS IMPACTING GROWTH OF PREFILLED SYRINGES MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN PREFILLED SYRINGES MARKET, BY TYPE, MATERIAL, DESIGN, AND REGION (2025)
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9
INCREASING HEALTHCARE EXPENDITURE AND RISING PREVALENCE OF CHRONIC DISEASES AMONG OLDER POPULATION TO DRIVE MARKET
FIGURE 10
NORTH AMERICA TO DOMINATE MARKET SHARE THROUGHOUT FORECAST PERIOD
FIGURE 11
JAPAN AND CONVENTIONAL PREFILLED SYRINGES ACCOUNTED FOR LARGEST ASIA PACIFIC PREFILLED SYRINGES MARKET SHARE IN 2025
FIGURE 12
CHINA TO GROW AT HIGHEST CAGR DURING STUDY PERIOD
FIGURE 13
EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES FROM 2026 TO 2031
FIGURE 14
PREFILLED SYRINGES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15
PREFILLED SYRINGES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16
PREFILLED SYRINGES MARKET: VALUE CHAIN ANALYSIS
FIGURE 17
PREFILLED SYRINGES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN PREFILLED SYRINGES MARKET
FIGURE 19
INVESTMENT/VENTURE CAPITAL SCENARIO IN PREFILLED SYRINGES MARKET, 2021–2024
FIGURE 20
GLOBAL PATENT PUBLICATION TRENDS (JANUARY 2014–DECEMBER 2025)
FIGURE 21
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PREFILLED SYRINGE PATENTS (JANUARY 2014−NOVEMBER 2025)
FIGURE 22
TOP APPLICANT COUNTRIES/REGIONS PATENTS FOR PREFILLED SYRINGES (JANUARY 2014−NOVEMBER 2025)
FIGURE 23
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PREFILLED SYRINGES
FIGURE 24
KEY BUYING CRITERIA FOR PREFILLED SYRINGES, BY TYPE
FIGURE 25
PREFILLED SYRINGES MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 26
NORTH AMERICA: PREFILLED SYRINGES MARKET SNAPSHOT
FIGURE 27
ASIA PACIFIC: PREFILLED SYRINGES MARKET SNAPSHOT
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN PREFILLED SYRINGES MARKET, 2020–2024 (USD MILLION)
FIGURE 29
PREFILLED SYRINGES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2024
FIGURE 30
PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 31
PREFILLED SYRINGES MARKET: COMPANY FOOTPRINT
FIGURE 32
PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025
FIGURE 33
BRAND/PRODUCT COMPARATIVE ANALYSIS IN PREFILLED SYRINGES MARKET
FIGURE 34
EV/EBITDA OF KEY VENDORS
FIGURE 35
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 36
R&D EXPENDITURE OF KEY PLAYERS AS PERCENTAGE OF TOTAL REVENUE, 2022–2024
FIGURE 37
BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
FIGURE 38
GERRESHEIMER AG: COMPANY SNAPSHOT
FIGURE 39
SCHOTT: COMPANY SNAPSHOT
FIGURE 40
WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 41
APTARGROUP, INC.: COMPANY SNAPSHOT
FIGURE 42
NIPRO: COMPANY SNAPSHOT
FIGURE 43
BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY SNAPSHOT
FIGURE 44
WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY SNAPSHOT
FIGURE 45
NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 46
STEVANATO GROUP: COMPANY SNAPSHOT
FIGURE 47
PREFILLED SYRINGES MARKET: RESEARCH DESIGN
FIGURE 48
PREFILLED SYRINGES MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 49
PREFILLED SYRINGES MARKET: PRIMARY SOURCES
FIGURE 50
PREFILLED SYRINGES MARKET: KEY DATA FROM PRIMARY SOURCES
FIGURE 51
KEY INSIGHTS FROM INDUSTRY PLAYERS IN PREFILLED SYRINGES MARKET
FIGURE 52
PREFILLED SYRINGES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
FIGURE 53
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 54
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 55
SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 56
REVENUE SHARE ANALYSIS ILLUSTRATION FOR BECTON, DICKINSON AND COMPANY (BD) (2025)
FIGURE 57
SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION (2025)
FIGURE 58
PREFILLED SYRINGES MARKET: TOP-DOWN APPROACH
FIGURE 59
CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2026–2031)
FIGURE 60
PREFILLED SYRINGES MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)
FIGURE 61
PREFILLED SYRINGES MARKET: DATA TRIANGULATION METHODOLOGY
Methodology
This study involved four major activities in estimating the current prefilled syringes market size. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the prefilled syringes market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the prefilled syringes market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the prefilled syringes market is provided below:
**Others include sales, marketing, and product managers.
Note 1: C-level executives include CEOs, COOs, and CTOs.
Note 2: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The research methodology used to estimate the size of the prefilled syringes market includes the following details.
The market sizing of the market was undertaken from the global side.
Country-level Analysis: The size of the prefilled syringes market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products and services in the overall prefilled syringes market was obtained from secondary data and validated by primary participants to arrive at the total prefilled syringes market. Primary participants further validated the numbers.
Geographic Market Assessment (By Region & Country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by prefilled syringes and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall prefilled syringes market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.
Prefilled Syringes Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Prefilled syringes are a convenient way to deliver parenteral medications or a single-dose packet of medication with a premeasured dose. This method of drug administration offers advantages for manufacturers in terms of reducing drug waste and extending product lifespan. Additionally, it provides ease of self-administration for patients at home and in non-hospital settings. Some examples of drugs packaged in prefilled syringes include biologics, vaccines, blood stimulants, therapeutic proteins, erythropoietin products, and interferons.
Key Stakeholders
- Product manufacturers, distributors, and suppliers
- Research laboratories
- Academic universities and medical research centers
- R&D centers
- Business research and consulting firms
- Biotechnology companies
- Hospitals
- Clinical centers
- Pharmaceutical companies
- Medical research laboratories
- Consulting firms
Report Objectives
- To describe, analyze, and forecast the prefilled syringes market by type, design, material, application, and region
- To describe and forecast the prefilled syringes market for key regions—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
- To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the prefilled syringes market
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
- To profile key players and comprehensively analyze their market shares and core competencies in the prefilled syringes market
- To analyze competitive developments such as partnerships, collaborations, agreements & acquisitions, product launches, expansions, and R&D activities in the prefilled syringes market
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
- Further breakdown of the Rest of Europe prefilled syringes market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
- Further breakdown of the Rest of Asia Pacific prefilled syringes market into Indonesia, Philippines, Vietnam, Hong Kong, and other countries
- Further breakdown of the Rest of Latin America prefilled syringes market into Colombia, Peru, and other countries.
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Prefilled Syringes Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Prefilled Syringes Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore Prefilled Syringes Intelligence
Powered by 17 years of MarketsandMarkets intelligence
